De Duve Institute


Complete publication list (Pubmed search):

>> Link

Representative publications:

IL-9 promotes IL-13-dependent paneth cell hyperplasia and up-regulation of innate immunity mediators in intestinal mucosa.
Steenwinckel V, Louahed J, Lemaire MM, Sommereyns C, Warnier G, McKenzie A, Brombacher F, Van Snick J, Renauld JC.
J Immunol. 2009. 182:4737-43.

Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22.
de Moura PR, Watanabe L, Bleicher L, Colau D, Dumoutier L, Lemaire MM, Renauld JC, Polikarpov I.
FEBS Lett. 2009. 583:1072-7.

Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice.
Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, Matthys P.
Arthritis Rheum. 2009. 60:390-5.

Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
Hornakova T, Staerk J, Royer Y, Flex E, Tartaglia M, Constantinescu SN, Knoops L, Renauld JC.
J Biol Chem. 2009. 284:6773-81.

The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins.
Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B.
Nature. 2008. 453:106-9.

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.
Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, Ariola C, Fodale V, Clappier E, Paoloni F, Martinelli S, Fragale A, Sanchez M, Tavolaro S, Messina M, Cazzaniga G, Camera A, Pizzolo G, Tornesello A, Vignetti M, Battistini A, Cavé H, Gelb BD, Renauld JC, Biondi A, Constantinescu SN, Foà R, Tartaglia M.
J Exp Med. 2008. 205:751-8.

JAK kinases overexpression promotes in vitro cell transformation.
Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC.
Oncogene. 2008. 27:1511-9.

IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells.
Steenwinckel V, Louahed J, Orabona C, Huaux F, Warnier G, McKenzie A, Lison D, Levitt R, Renauld JC.
J Immunol. 2007. 178:3244-51.

IL-9 and its receptor: from signal transduction to tumorigenesis.
Knoops L, Renauld JC.
Growth Factors. 2004. 22:207-15. Review.

Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators.
Renauld JC.
Nat Rev Immunol. 2003. 3:667-76. Review.

CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I.
Louahed J, Struyf S, Demoulin JB, Parmentier M, Van Snick J, Van Damme J, Renauld JC.
Eur J Immunol. 2003. 33:494-501.

Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10.
Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC.
J Biol Chem. 2002. 277:33676-82.

Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types.
Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC.
J Immunol. 2001. 167:3545-9.

New insights into the role of cytokines in asthma.
Renauld JC.
J Clin Pathol. 2001. 54:577-89. Review.

Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22.
Dumoutier L, Lejeune D, Colau D, Renauld JC.
J Immunol. 2001. 166:7090-5.

STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells.
Demoulin JB, Uyttenhove C, Lejeune D, Mui A, Groner B, Renauld JC.
Cancer Res. 2000. 60:3971-7.

Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9.
Dumoutier L, Louahed J, Renauld JC.
J Immunol. 2000. 164:1814-9.

Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice.
Richard M, Grencis RK, Humphreys NE, Renauld JC, Van Snick J.
Proc Natl Acad Sci U S A. 2000. 97:767-72.

Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor.
Dumoutier L, Van Roost E, Colau D, Renauld JC.
Proc Natl Acad Sci U S A. 2000. 97:10144-9.

Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice.
Godfraind C, Louahed J, Faulkner H, Vink A, Warnier G, Grencis R, Renauld JC.
J Immunol. 1998. 160:3989-96.

I-309/T cell activation gene-3 chemokine protects murine T cell lymphomas against dexamethasone-induced apoptosis.
Van Snick J, Houssiau F, Proost P, Van Damme J, Renauld JC.
J Immunol. 1996. 157:2570-6.

Interleukin-9 is a major anti-apoptotic factor for thymic lymphomas.
Renauld JC, Vink A, Louahed J, Van Snick J.
Blood. 1995. 85:1300-5.

Thymic lymphomas in interleukin 9 transgenic mice.
Renauld JC, van der Lugt N, Vink A, van Roon M, Godfraind C, Warnier G, Merz H, Feller A, Berns A, Van Snick J.
Oncogene. 1994. 9:1327-32.

Expression cloning of the murine and human interleukin 9 receptor cDNAs.
Renauld JC, Druez C, Kermouni A, Houssiau F, Uyttenhove C, Van Roost E, Van Snick J.
Proc Natl Acad Sci U S A. 1992. 89:5690-4.

Human P40/IL-9. Expression in activated CD4+ T cells, genomic organization, and comparison with the mouse gene.
Renauld JC, Goethals A, Houssiau F, Merz H, Van Roost E, Van Snick J.
J Immunol. 1990. 144:4235-41.